A novel oncolytic virus engineered with PD-L1 scFv effectively inhibits tumor growth in a mouse model

作     者：Chuanjian Wu Manman Wu Minglong Liang Sidong Xiong Chunsheng Dong 

作者机构：Jiangsu Key Laboratory of Infection and ImmunityThe Institutes of Biology and Medical SciencesSoochow University199 Ren-Ai RoadSuzhou 215123 JiangsuChina 

基　　金：supported by the National Natural Science Foundation of China(31470848,31470880,31670898,81802083 and 31870867) State Key Laboratory of Veterinary Biotechnology Foundation(SKLVBF201916) Jiangsu Provincial Innovative Research Team,the Priority Academic Program Development of Jiangsu Higher Education Institutions 

出 版 物：《Cellular & Molecular Immunology》 (中国免疫学杂志（英文版）)

年 卷 期：2019年第16卷第9期

页      码：780-782页

摘      要：The adoptive transfer of engineered chimeric antigen receptor(CAR)T cells has yielded impressive clinical results for targeting hematological cancers.1 However,the advancement of CAR T-cell therapy in solid tumors remains limited,due to the scarcity of tumor antigens that are deemed safe for ***,the requirement of patient-specific autologous T cells for the current standard treatment has also hampered its *** virus(OV)therapy has been classified as another form of novel immunotherapy.

主 题 词：therapy clinical engineered 

学科分类：1002[医学-临床医学类] 100214[100214] 10[医学] 

核心收录：

D　O　I：10.1038/s41423-019-0264-7

馆 藏 号：203692815...